Free Trial
NASDAQ:VRPX

Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

Virpax Pharmaceuticals logo
$0.01 +0.00 (+11.82%)
As of 08/22/2025 03:45 PM Eastern

About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)

Key Stats

Today's Range
$0.0111
$0.0123
50-Day Range
$0.01
$0.46
52-Week Range
$0.01
$26.25
Volume
1,734 shs
Average Volume
169,058 shs
Market Capitalization
$15.28 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Receive VRPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRPX Stock News Headlines

Virpax Pharmaceuticals Inc trading halted, news pending
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.tc pixel
Virpax receives positive Probudur results for dose range study
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
See More Headlines

VRPX Stock Analysis - Frequently Asked Questions

Virpax Pharmaceuticals' stock was trading at $9.4975 on January 1st, 2025. Since then, VRPX stock has decreased by 99.9% and is now trading at $0.0123.

Virpax Pharmaceuticals's stock reverse split on the morning of Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Virpax Pharmaceuticals (VRPX) raised $15 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Dare Bioscience (DARE), Rallybio (RLYB), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS).

Company Calendar

Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VRPX
CIK
1708331
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.19 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,554.34%
Return on Assets
-338.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.13
Quick Ratio
0.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.65 per share
Price / Book
0.01

Miscellaneous

Outstanding Shares
1,242,000
Free Float
4,707,000
Market Cap
$15.28 thousand
Optionable
Not Optionable
Beta
1.49
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:VRPX) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners